AbCellera Biologics WKN: A2QKXS ISIN: CA00288U1066 Kürzel: ABCL Forum: Aktien Thema: Hauptdiskussion

Bald sind Wir wie ich es gesagt habe unter 2 doller

Q & A Highlights Q: Can you update us on the competitive landscape for OX40 ligand targeted therapy, particularly in light of recent data from rocatinlimab? A: Carl Hansen, CEO, explained that rocatinlimab's recent data highlights the differences between OX40 and OX40 ligand therapies. Rocatinlimab is a depleting antibody, whereas AbCellera's 575 is non-depleting. The recent data suggests that non-depleting OX40 ligand antibodies, like 575, may have an advantage. AbCellera remains optimistic about the potential of 575 in atopic dermatitis and other indications. Q: What extent of data can we expect at SITC for the T-cell engagers? A: Carl Hansen, CEO, stated that they will present updated data from the T-cell engager platform, highlighting programs demonstrating desired profiles in killing and cytokine response. They will also present work on trispecific TCEs designed for better sustained T-cell killing. Q: How many TCE programs do you think you could push forward independently without a broader partnership? A: Carl Hansen, CEO, mentioned that AbCellera has built core capabilities to develop antibody therapies and has nearly $900 million in liquidity. They anticipate advancing two to three new development candidates per year starting next year, with sufficient funding for over three years of pipeline investments. Q: Is there a requisite amount of clinical development work that needs to occur through Canadian trial sites due to government funding? A: Andrew Booth, CFO, confirmed that Phase 1 trials for molecules funded by the Canadian government will be conducted in Canada. They do not anticipate issues with this requirement for current trials and can expand to other countries if necessary. Q: Can you provide more details about ABCL635, its target market, and competitiveness? A: Carl Hansen, CEO, stated that ABCL635 is a first-in-class antibody for endocrine or metabolic disorders targeting a multipass transmembrane protein. The addressable market is estimated to exceed $2 billion, but further details will be disclosed upon CTA approval. https://www.gurufocus.com/news/2582653/abcellera-biologics-inc-abcl-q3-2024-earnings-call-highlights-navigating-challenges-with-strategic-developments?r=4bf001661e6fdd88d0cd7a5659ff9748

AbCellera Biologics: Promising Investment with Robust Antibody Platform and Strategic Growth Plans Brian Anderson Nov 06, 2024, 09:19 AM Leerink Partners analyst Puneet Souda has reiterated their bullish stance on ABCL stock, giving a Buy rating yesterday. Puneet Souda has given his Buy rating due to a combination of factors that highlight AbCellera Biologics as a promising investment. The company possesses a robust antibody discovery platform and a substantial liquidity position exceeding $800 million, which it is utilizing to develop its internal pipeline and establish strategic partnerships. Despite limited updates in the third quarter of 2024, the company remains on track with its timelines for clinical trial applications and the first commercial lot shipment from its GMP facility. The stock is currently trading near its total liquidity, suggesting potential upside from its royalty portfolio and internal pipeline. Management anticipates providing significant preclinical data in the second quarter of 2025, which could enhance recognition of the platform’s value. Additionally, AbCellera is prioritizing its preclinical candidate molecules and carefully managing its capital deployment, believing it has sufficient capital for three years to generate clinical data and attract interest from potential partners. According to TipRanks, Souda is an analyst with an average return of -14.1% and a 34.28% success rate. Souda covers the Healthcare sector, focusing on stocks such as Illumina, Exact Sciences, and Quanterix. In another report released yesterday, Stifel Nicolaus also maintained a Buy rating on the stock with a $12.00 price target. https://www.tipranks.com/news/blurbs/abcellera-biologics-promising-investment-with-robust-antibody-platform-and-strategic-growth-plans?mod=mw_quote_news

AbCellera presents data on applications of T-cell engager platform at SITC TheFly Nov 07, 2024, 04:10 PM AbCellera (ABCL) announced new data on its T-cell engager, or TCE, platform, to be presented as a poster at the Society for Immunotherapy of Cancer, or SITC, 39th Annual Meeting. AbCellera’s presentation describes strategies to address key challenges in TCE development and preclinical characterization of TCEs against solid tumor targets B7-H4 and PSMA show tumor-cell killing and cytokine release profiles that are differentiated from clinical benchmarks, the company noted. https://www.tipranks.com/news/the-fly/abcellera-presents-data-on-applications-of-t-cell-engager-platform-at-sitc?mod=mw_quote_news

https://abcellera.com/post/sitc2024/

Wenn trump gewinnen sollte sehen wir maximal 5 Euro dann wieder Berg ab

So ein drecksladen ohne witz

Steht Was an oder leuten in 2 Jahren in Insolvenz Glocken 😁

Was steht an bei diesem.abficker wann wird Was wieder entdeckt oder zusammen arbeiten gemacht??

Ich denke das es geht um den CEO.

https://www.investing.com/news/company-news/thermopylae-holdings-ltd-buys-740k-of-abcellera-biologics-shares-93CH-3594242

Beim Investieren kann man mit seiner Entscheidung lange alleine sein. Dies ist die beste und wertvollste Zeit für mich! Warum? Weil ich mich in dieser Zeit selbst hinterfrage, prüfe und reflektiere ob meine Entscheidung richtig ist. Als Investor habe ich nicht nur dreimal alleine mit meiner Entscheidung gestanden. Doch habe ich, die für mich, nötigen Hausaufgaben gemacht und mich vom Aktienkurs und der Masse nicht beirren lassen. Börse ist Schach und nicht Dame. Die Meister J. Templeton und P. Fischer haben mir nach einer Reihe von Kausalitäten die Augen geöffnet. Fokussiert, konzentriert, investiert. Schauen wir uns AbCellera Bilogics an, anhand zwei älterer Artikel: https://www.sharedeals.de/abcellera-aktie-nach-den-quartalszahlen-kaufen/#gref https://www.sharedeals.de/abcellera-biologics-spannender-ki-player/#gref Ebenfalls schauen wir uns die Gegenwart an: Der Wert scheint noch keinen Boden zu haben. Was wir nicht zuviel an Bedeutung geben sollten. Die Marktkapitalisierung liegt derzeit zwischen 600-700 Millionen Euro. Fakt ist, es besteht Cash von ca. 700 Millionen in der Bilanz. Desweiteren stehen 401 Millionen von ihrem Heimatland Kanada zur Verfügung. Dies macht in der Summe ca. 1,1 Milliarden an Finanzpower. Auch CFO Andrew Booth erwähnte dies innerhalb der letzten zwei Quartale, da dieser Punkt nicht in die Bilanz einfließen tut. Der Mindestwert pro Aktie, anhand dieser zwei Fakten, liegt bei ca. 3,30€ ! Nicht einbezogen sind: Lizensen, geistiges Eigentum, Technologien, Pipeline, Partnerschaften und etc. ... Wir haben andere Zeiten, wo wir mehr und mehr exponentielle Bewegungen erleben werden. Und das selbst aktuell bei hohen Zinssätzen. Sinken die Zinsen erst, wird es noch exponentieller. By the Way: Dies ist meine Meinung und ich bin seit 04/21 investiert. In diesem Sinne: Fokussiert euch, konzentriert euch und investiert. Denn Energie folgt der Aufmerksamkeit ;)

AbCellera Biologics Inc. (ABCL): A Top Contender Among Canada’s Best Penny Stocks in 2024 Umar Farooq Thu, Aug 29, 2024, 11:13 AM GMT+28 min read We recently compiled a list of the 10 Best Canadian Penny Stocks to Buy Now. In this article, we are going to take a look at where AbCellera Biologics Inc. (NASDAQ:ABCL) stands against the other Canadian penny stocks. https://finance.yahoo.com/news/abcellera-biologics-inc-abcl-top-091302271.html

Wir haben bisher keinen Boden bestätigt. Alles invalidiert. Der Trend ist stark bearish. Bodenbildung kann man nur mutmaßen. Das mache ich auch für mich und bleibe dabei. Sammle weiter ein wenn es soweit ist.

September unter 2 Euro 😇